TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 04:30PM GMT
Release Date Price: €31.29 (-4.11%)
Matthew Kaplan
Ladenburg Thalmann & Co. Inc., - Analyst

Good afternoon. It's my pleasure to introduce our next presenting company, TG Therapeutics. Presenting for the Company today is CEO Mike Weiss. Mike, thanks for joining us at the conference. And we are going to have this as a fireside chat, so it should be fun.

I guess for the people who are not familiar with TG, can you give us kind of a brief background on the Company and your overall vision for the Company as well to start with?

Mike Weiss
TG Therapeutics, Inc. - Executive Chairman, President and CEO

Yes, sure, absolutely. Thanks for having us, Matt. Really appreciate it, and great to see you. So TG, we founded TG in 2012. The mission has been and continues to be about providing the best treatment options possible for patients with B cell diseases. So that includes cancers like chronic lymphocytic leukemia, marginal zone lymphoma and follicular lymphoma. And on the autoimmune side, B cell diseases include MS, where we have a large program, and other areas, including lupus, RA could be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot